IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(d) |
Appointment of Director |
On July 17, 2017, Ann D. Rhoads was appointed to the board of directors (the “Board”) of IRIDEX Corporation (the “Company”) and the compensation committee and the audit committee of the Board, in each case effective immediately. Ms. Rhoads replaced George Marcellino, Ph.D. on the compensation committee.
Ms. Rhoads will receive standard compensation available to non-employee members of the Board and committees of the Board and an option to purchase 15,000 shares of the Company’s common stock which vests in equal monthly installments over four years following the effective date of the grant. In addition, it is expected that Ms. Rhoads will execute the Company’s standard form of indemnification agreement.
The Company’s press release dated July 18, 2017 regarding Ms. Rhoad’s appointment is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated July 18, 2017. |
IRIDEX CORP ExhibitEX-99.1 2 irix-ex991_6.htm EX-99.1 irix-ex991_6.htm Exhibit 99.1 IRIDEX ANNOUNCES APPOINTMENT OF ANN RHOADS TO ITS BOARD OF DIRECTORS MOUNTAIN VIEW,…To view the full exhibit click here
About IRIDEX CORPORATION (NASDAQ:IRIX)
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.